ZA200105222B - Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (MMP) inhibitors/TNF-alpha converting enzyme (TACE) inhibitors. - Google Patents

Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (MMP) inhibitors/TNF-alpha converting enzyme (TACE) inhibitors. Download PDF

Info

Publication number
ZA200105222B
ZA200105222B ZA200105222A ZA200105222A ZA200105222B ZA 200105222 B ZA200105222 B ZA 200105222B ZA 200105222 A ZA200105222 A ZA 200105222A ZA 200105222 A ZA200105222 A ZA 200105222A ZA 200105222 B ZA200105222 B ZA 200105222B
Authority
ZA
South Africa
Prior art keywords
phenyl
sulfonyl
methyl
ynyloxy
hydroxy
Prior art date
Application number
ZA200105222A
Other languages
English (en)
Inventor
Jeremy Ian Levin
James Ming Chen
Vincent Premarana Sandanayaka
Jannie Lea Baker
Aranapakam Mudumbai Venkatesan
Arie Zask
Mila Ti Du
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of ZA200105222B publication Critical patent/ZA200105222B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C07D211/66—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having a hetero atom as the second substituent in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA200105222A 1999-01-27 2001-06-25 Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (MMP) inhibitors/TNF-alpha converting enzyme (TACE) inhibitors. ZA200105222B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23803899A 1999-01-27 1999-01-27

Publications (1)

Publication Number Publication Date
ZA200105222B true ZA200105222B (en) 2002-09-25

Family

ID=22896246

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200105222A ZA200105222B (en) 1999-01-27 2001-06-25 Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (MMP) inhibitors/TNF-alpha converting enzyme (TACE) inhibitors.

Country Status (13)

Country Link
JP (1) JP2002535390A (cs)
KR (1) KR20010101732A (cs)
AR (1) AR035312A1 (cs)
AT (1) ATE309986T1 (cs)
AU (1) AU769418B2 (cs)
CA (1) CA2356313A1 (cs)
CZ (1) CZ20012711A3 (cs)
DE (1) DE60024056D1 (cs)
EA (1) EA200100806A1 (cs)
HU (1) HUP0200223A3 (cs)
IL (1) IL144345A0 (cs)
NZ (1) NZ512566A (cs)
ZA (1) ZA200105222B (cs)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004060875A1 (ja) * 2002-12-26 2004-07-22 Carna Biosciences Inc. アルキニル基置換アザ糖誘導体およびそれを有効成分とする薬剤
KR20090042779A (ko) * 2006-06-30 2009-04-30 쉐링 코포레이션 Ｐ53 활성을 증가시키는 치환된 피페리딘 및 이의 사용
CA2724887A1 (en) * 2008-06-02 2009-12-10 Cipla Limited Processes for the synthesis of levocetirizine and intermediates for use therein

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000075809A (ko) * 1997-02-27 2000-12-26 윌리암 에이취 캘넌, 에곤 이 버그 매트릭스 메탈로프로테이나제 억제제로서의 ｎ-하이드록시-2-(알킬, 아릴 또는 헤테로아릴 설파닐, 설피닐 또는 설포닐)-3-치환된 알킬, 아릴 또는 헤테로아릴아미드
IL137566A0 (en) * 1998-02-19 2001-07-24 American Cyanamid Co N-hydroxy-2-(alkyl, aryl or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted-alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors

Also Published As

Publication number Publication date
HUP0200223A3 (en) 2002-12-28
HUP0200223A2 (en) 2002-06-29
EA200100806A1 (ru) 2002-08-29
AU769418B2 (en) 2004-01-29
AR035312A1 (es) 2004-05-12
JP2002535390A (ja) 2002-10-22
CA2356313A1 (en) 2000-08-03
KR20010101732A (ko) 2001-11-14
NZ512566A (en) 2004-02-27
ATE309986T1 (de) 2005-12-15
CZ20012711A3 (cs) 2002-05-15
DE60024056D1 (de) 2005-12-22
IL144345A0 (en) 2002-05-23
AU2630500A (en) 2000-08-18

Similar Documents

Publication Publication Date Title
RU2230736C2 (ru) Содержащие гетероциклическую боковую цепь ингибиторы металлопротеиназы и фармацевтическая композиция
EP0531410B1 (en) (+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(fluorophenyl)ethyl]-4-piperidinemethanol
US8697865B2 (en) Cyclic amide derivative, and its production and use
CN104334559A (zh) 新型β-内酰胺酶抑制剂及其制备方法
JP2001513484A (ja) 非環式メタロプロテアーゼ阻害剤
KR20010042694A (ko) 치환 피롤리딘 히드록사메이트 메탈로프로테아제 억제제
EP1147085B1 (en) Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (mmp) inhibitors / tnf-alpha converting enzyme (tace) inhibitors
ZA200105066B (en) Alkynyl containing hydroxamic acid compounds as TACE inhibitors.
US20020147342A1 (en) Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
US6949545B2 (en) Heterocyclic side chain containing, n-substituted metalloprotease inhibitors
ZA200105222B (en) Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (MMP) inhibitors/TNF-alpha converting enzyme (TACE) inhibitors.
ES2238468T3 (es) Derivados de aza-aminoacidos (inhibidores del factor xa15).
US6753337B2 (en) Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
CN102470128A (zh) 用于对老年和肾损伤非st抬高型心肌梗塞患者进行治疗的奥米沙班
US20020049193A1 (en) N-linked sulfonamides of heterocyclic thioesters
MXPA01007573A (en) Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (mmp) inhibitors/tnf-alpha converting enzyme (tace) inhibitors
JPH10101563A (ja) 抗酸化剤